NCT06205706 - BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

July 14, 2027

Study Completion Date

November 7, 2028

Conditions

Solid TumorsNon Small Cell Lung CancerHepatocellular Carcinoma

Interventions

DRUG

BI-1910

BI-1910 administered as a flat-dose IV infusion once every 3 weeks

DRUG

Pembrolizumab

Pembrolizumab be administered as an IV infusion at its standard flat dose (200 mg) once every 3 weeks prior to the BI-1910 infusion

Trial Locations (8)

Rigshospitalet, Copenhagen

Universitätsklinikum Essen, Essen

HM Sanchinarro, Madrid

Hospital Fundacion Jimenez Diaz, Madrid

Hospital universitario Virgen del Rocio, Seville

Lund University Hospital, Lund

Karolinska University Hospital, Solna, Stockholm

Hospital HM Nou Delfos, Barcelona